WCM
CNTA

Wildcat Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Wildcat Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-281,859
Closed -$4.05M – 7
2025
Q1 		$4.05M Buy
+281,859
New +$4.61M 2.16% 6

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wildcat Capital Management's CNTA Position: Q2 2025 in Review

Wildcat Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 281,859 shares — an estimated $4.05M sold.

Wildcat Capital Management first reported a position in CNTA in Q1 2025 and held it in 1 quarter. The position peaked at $4.05M in Q1 2025. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Wildcat Capital Management reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Wildcat Capital Management sold 281,859 Centessa Pharmaceuticals shares in Q2 2025, an estimated $4.05M.
  • Wildcat Capital Management first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Wildcat Capital Management's Centessa Pharmaceuticals position peaked at $4.05M in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Wildcat Capital Management's 13F filing for Q2 2025, filed 18 Jul 2025.